These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32535092)

  • 1. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.
    Roberts J; Ennis D; Hudson M; Ye C; Saltman A; Himmel M; Rottapel R; Pope J; Hoa S; Tisseverasinghe A; Fifi-Mah A; Maltez N; Jamal S
    Autoimmun Rev; 2020 Aug; 19(8):102595. PubMed ID: 32535092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
    Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
    Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
    Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
    Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy].
    Verspohl SH; Schulze-Koops H; Heine A; Schäfer VS
    Z Rheumatol; 2020 Oct; 79(8):797-808. PubMed ID: 32926217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
    Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.
    Richter MD; Pinkston O; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
    Arthritis Rheumatol; 2018 Mar; 70(3):356-360. PubMed ID: 29363290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
    Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
    Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
    Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
    Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M; Truchetet ME; Schaeverbeke T
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy.
    Dey A; Manolios N; Long GV; Carlino MS; Kefford R; Schrieber L
    Intern Med J; 2022 May; 52(5):818-827. PubMed ID: 33135853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
    Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
    Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
    Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
    Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of sequential immune checkpoint inhibitors after prior immune therapy.
    Awidi M; Connell B; Johnson D; Craven I; Ranjit R; Gil B; Dal'Bo N; Maher L; Daves SR; McDonald S; Gunturu KS
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2375-2382. PubMed ID: 35727369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between immune-related adverse event timing and treatment outcomes.
    Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
    Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.